[go: up one dir, main page]

MX2019012260A - Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga. - Google Patents

Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga.

Info

Publication number
MX2019012260A
MX2019012260A MX2019012260A MX2019012260A MX2019012260A MX 2019012260 A MX2019012260 A MX 2019012260A MX 2019012260 A MX2019012260 A MX 2019012260A MX 2019012260 A MX2019012260 A MX 2019012260A MX 2019012260 A MX2019012260 A MX 2019012260A
Authority
MX
Mexico
Prior art keywords
bladder cancer
dna methylation
analysis methods
mutational analysis
cancer surveillance
Prior art date
Application number
MX2019012260A
Other languages
English (en)
Inventor
Crager Michael
Knezevic Dejan
Lopatin Margarita
Febbo Phillip
Tsiatis Athanasios
N Silk Christopher
P Miller David
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2019012260A publication Critical patent/MX2019012260A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente descripción se refiere a métodos para verificar pacientes con cáncer de vejiga y analizar muestras de pacientes para detectar la presencia de ADN metilado y opcionalmente mutaciones genéticas particulares. En algunas modalidades, los resultados del análisis son correlacionados con mediciones de resultados clínicos tales como el riesgo de recurrencia del cáncer de vejiga.
MX2019012260A 2017-05-18 2018-05-17 Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga. MX2019012260A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508274P 2017-05-18 2017-05-18
PCT/US2018/033146 WO2018213550A1 (en) 2017-05-18 2018-05-17 Dna methylation and mutational analysis methods for bladder cancer surveillance

Publications (1)

Publication Number Publication Date
MX2019012260A true MX2019012260A (es) 2020-01-27

Family

ID=62528860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012260A MX2019012260A (es) 2017-05-18 2018-05-17 Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga.

Country Status (11)

Country Link
US (2) US11649506B2 (es)
EP (1) EP3625369B1 (es)
JP (1) JP2020519296A (es)
CN (1) CN110621788B (es)
AU (1) AU2018269030A1 (es)
BR (1) BR112019022360A2 (es)
ES (1) ES2973607T3 (es)
IL (1) IL269707A (es)
MX (1) MX2019012260A (es)
SG (2) SG10201912359XA (es)
WO (1) WO2018213550A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912359XA (en) * 2017-05-18 2020-02-27 Genomic Health Inc Dna methylation and mutational analysis methods for bladder cancer surveillance
KR102164432B1 (ko) * 2019-09-18 2020-10-13 한국과학기술원 Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
AU2021238717A1 (en) * 2020-03-20 2022-08-25 Singlera Health Technologies (Shanghai) Ltd. Methods and kits for screening colorectal neoplasm
CN114634982A (zh) * 2020-12-15 2022-06-17 广州市基准医疗有限责任公司 一种检测多核苷酸变异的方法
CN113621691A (zh) * 2021-09-27 2021-11-09 广东省妇幼保健院 基于一代测序技术直接检测KLF1基因启动子区CpG甲基化的方法和试剂盒
CN116013528B (zh) * 2023-01-10 2023-11-24 中山大学孙逸仙纪念医院 结合fish检测的膀胱癌术后复发风险预测方法、装置及介质
CN116987787B (zh) * 2023-06-09 2024-07-30 北京泛生子基因科技有限公司 检测膀胱癌是否复发的装置和计算机可读存储介质
TWI886817B (zh) * 2023-06-09 2025-06-11 臺北醫學大學 甲基化生物標記用於篩檢泌尿道上皮癌的方法
CN117604101B (zh) * 2023-09-11 2025-02-25 北京橡鑫生物科技有限公司 一种基因标志物组合、试剂盒及检测方法
CN118006781B (zh) * 2024-02-27 2025-01-07 广州中鑫基因医学科技有限公司 用于检测尿路上皮癌的标志物、引物组、高敏感性和高特异性的试剂盒及检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534465T1 (de) 2005-06-23 2011-12-15 Biocartis Sa Kartusche, system und verfahren für automatisierte medizinische diagnosen
ES2721424T3 (es) * 2009-04-20 2019-07-31 Univ Erasmus Med Ct Rotterdam Método de diagnóstico del cáncer de vejiga
ES2669439T3 (es) 2009-06-26 2018-05-25 Epigenomics Ag Métodos y ácidos nucleicos para el análisis del carcinoma de vejiga
CN103417983A (zh) * 2012-05-18 2013-12-04 北京大学 新的凋亡相关分子tmem106a及其用途
WO2014085666A1 (en) * 2012-11-27 2014-06-05 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
CN105705653A (zh) * 2013-05-10 2016-06-22 南加州大学 针对膀胱癌的dna甲基化生物标志物
US20160340740A1 (en) 2014-01-30 2016-11-24 The Regents Of The University Of California Methylation haplotyping for non-invasive diagnosis (monod)
GB201511152D0 (en) * 2015-06-24 2015-08-05 Ucl Business Plc Method of diagnosing bladder cancer
SG10201912359XA (en) * 2017-05-18 2020-02-27 Genomic Health Inc Dna methylation and mutational analysis methods for bladder cancer surveillance

Also Published As

Publication number Publication date
IL269707A (en) 2019-11-28
AU2018269030A1 (en) 2019-10-17
CN110621788A (zh) 2019-12-27
EP3625369B1 (en) 2024-02-14
BR112019022360A2 (pt) 2020-05-19
SG11201909113VA (en) 2019-10-30
US11649506B2 (en) 2023-05-16
EP3625369A1 (en) 2020-03-25
ES2973607T3 (es) 2024-06-20
SG10201912359XA (en) 2020-02-27
JP2020519296A (ja) 2020-07-02
WO2018213550A1 (en) 2018-11-22
US20200165686A1 (en) 2020-05-28
CA3057440A1 (en) 2018-11-22
US20230374604A1 (en) 2023-11-23
CN110621788B (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
MX2019012260A (es) Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga.
EP3640341A3 (en) Assays to determine dna methylation and dna methylation markers of cancer
EP4553840A3 (en) Systems and methods for analyzing nucleic acid
MY195999A (en) Molecular Detection/Diagnosis Reagent for Tumor
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
EP3274476A4 (en) Digital analysis of circulating tumor cells in blood samples
WO2015153732A8 (en) Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
WO2016201365A3 (en) Methods for treating cancers
WO2017053763A3 (en) ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
BR102015015096A2 (pt) método de detecção in vitro de câncer de tireoide em um paciente, método in vitro de diferenciação entre câncer de tireoide e tecido de tireoide normal ou de lesões benignas de tireoide, uso de um conjunto de genes, método de obtenção de dados para direcionamento do tratamento do cancer de tireoide, kit laboratorial e dispositivo para classificar uma amostra biológica de glândula tireoide como maligna ou benigna
WO2015021263A3 (en) Methylation biomarkers for colorectal cancer
Arastefar et al. The prevalence of CMV and EBV among the patients with the colorectal cancer; a molecular approach
UA99752U (uk) Спосіб прогнозування гематологічної токсичності хіміотерапії у хворих на рак грудної залози
UA96045U (uk) Спосіб прогнозування зрощення перелому
UA96046U (uk) Спосіб прогнозування зрощення перелому
UA96068U (uk) Спосіб прогнозування зрощення перелому
HK40073822A (en) Detection and treatment of residual disease using circulating tumor dna analysis
Wen-mei et al. Expression and clinical significance of ZFX in tissues from small cell lung cancer patients
UA96016U (uk) Спосіб прогнозування зрощення перелому
Yu et al. Patterns of somatic mutations in an Australian cohort of lung adenocarcinoma
UA96015U (uk) Спосіб прогнозування зрощення перелому
UA68920U (ru) Способ прогнозирования риска развития злокачественных новообразований